Pharmacological inhibition of USP13 with spautin-1 significantly inhibits tumor growth and increases tumor cell sensitivity to BH3 mimetic inhibitors, which suggests that targeting USP13 may be a valuable strategy for cancer treatment (41). This evidence concerns the gene USP13 and neoplasm.